225 related articles for article (PubMed ID: 10967185)
1. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Korshunov A; Golanov A; Timirgaz V
J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
3. Prognostic marker analysis in pediatric intracranial ependymomas.
McLendon RE; Lipp E; Satterfield D; Ehinger M; Austin A; Fleming D; Perkinson K; Lefaivre M; Zagzag D; Wiener B; Gururangan S; Fuchs H; Friedman HS; Herndon JE; Healy P
J Neurooncol; 2015 Apr; 122(2):255-61. PubMed ID: 25563815
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical markers for prognosis of oligodendroglial neoplasms.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):237-53. PubMed ID: 12187958
[TBL] [Abstract][Full Text] [Related]
5. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in intracranial ependymomas in children.
Figarella-Branger D; Civatte M; Bouvier-Labit C; Gouvernet J; Gambarelli D; Gentet JC; Lena G; Choux M; Pellissier JF
J Neurosurg; 2000 Oct; 93(4):605-13. PubMed ID: 11014538
[TBL] [Abstract][Full Text] [Related]
8. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
[TBL] [Abstract][Full Text] [Related]
9. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
Suri VS; Tatke M; Singh D; Sharma A
Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
[TBL] [Abstract][Full Text] [Related]
10. p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases.
Korshunov A; Golanov A; Timirgaz V
Acta Neuropathol; 2001 Sep; 102(3):271-7. PubMed ID: 11585252
[TBL] [Abstract][Full Text] [Related]
11. Supratentorial extraventricular ependymomas: A retrospective study focused on long-term outcomes and prognostic factors.
Wang M; Zhang R; Liu X; Li D; Qiu C; Zhao P; Zuo Y; Zhang P; Wang J; Sun H
Clin Neurol Neurosurg; 2018 Feb; 165():1-6. PubMed ID: 29253745
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of cyclin D1 is higher in supratentorial ependymomas and predicts relapses in gross total resection cases.
de Andrade FG; Marie SK; Uno M; Matushita H; Taricco MA; Teixeira MJ; Rosemberg S; Oba-Shinjo SM
Neuropathology; 2015 Aug; 35(4):312-23. PubMed ID: 25946121
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor and neovascularization in astrocytic tumors.
Takekawa Y; Sawada T
Pathol Int; 1998 Feb; 48(2):109-14. PubMed ID: 9589474
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of cell cycle/apoptosis regulators and epidermal growth factor receptor in pediatric intracranial ependymomas.
Alexiou GA; Stefanaki K; Moschovi M; Patereli A; Prodromou N; Karentzou O
J Child Neurol; 2011 Feb; 26(2):195-8. PubMed ID: 20713981
[TBL] [Abstract][Full Text] [Related]
15. Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients.
Chen C; Chen L; Yao Y; Qin Z; Chen H
J Neurooncol; 2016 Mar; 127(1):43-52. PubMed ID: 26615563
[TBL] [Abstract][Full Text] [Related]
16. Coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma of the esophagus.
Koide N; Nishio A; Hiraguri M; Hanazaki K; Adachi W; Amano J
Am J Gastroenterol; 2001 Jun; 96(6):1733-40. PubMed ID: 11419822
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical prognostic markers in intracranial ependymomas: systematic review and meta-analysis.
Kuncova K; Janda A; Kasal P; Zamecnik J
Pathol Oncol Res; 2009 Dec; 15(4):605-14. PubMed ID: 19301151
[TBL] [Abstract][Full Text] [Related]
18. Spinal ependymoma in adults: a multicenter investigation of surgical outcome and progression-free survival.
Wostrack M; Ringel F; Eicker SO; Jägersberg M; Schaller K; Kerschbaumer J; Thomé C; Shiban E; Stoffel M; Friedrich B; Kehl V; Vajkoczy P; Meyer B; Onken J
J Neurosurg Spine; 2018 Jun; 28(6):654-662. PubMed ID: 29521579
[TBL] [Abstract][Full Text] [Related]
19. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
[TBL] [Abstract][Full Text] [Related]
20. Study of stem cell marker nestin and its correlation with vascular endothelial growth factor and microvascular density in ependymomas.
Nambirajan A; Sharma MC; Gupta RK; Suri V; Singh M; Sarkar C
Neuropathol Appl Neurobiol; 2014 Oct; 40(6):714-25. PubMed ID: 24224478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
